Fox Run Management L.L.C. boosted its position in Merck & Co., Inc. (NYSE:MRK) by 39.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,018 shares of the company’s stock after acquiring an additional 2,263 shares during the period. Fox Run Management L.L.C.’s holdings in Merck & Co., Inc. were worth $569,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Rockland Trust Co. bought a new stake in Merck & Co., Inc. in the 2nd quarter worth $3,949,000. Sawyer & Company Inc grew its holdings in Merck & Co., Inc. by 10.7% in the 2nd quarter. Sawyer & Company Inc now owns 22,984 shares of the company’s stock worth $1,395,000 after acquiring an additional 2,215 shares during the last quarter. Steward Partners Investment Advisory LLC grew its holdings in Merck & Co., Inc. by 37.0% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 122,748 shares of the company’s stock worth $7,451,000 after acquiring an additional 33,153 shares during the last quarter. Jennison Associates LLC grew its holdings in Merck & Co., Inc. by 11.0% in the 2nd quarter. Jennison Associates LLC now owns 924,946 shares of the company’s stock worth $56,144,000 after acquiring an additional 91,879 shares during the last quarter. Finally, HL Financial Services LLC grew its holdings in Merck & Co., Inc. by 0.7% in the 2nd quarter. HL Financial Services LLC now owns 217,281 shares of the company’s stock worth $13,189,000 after acquiring an additional 1,540 shares during the last quarter. 72.33% of the stock is currently owned by institutional investors and hedge funds.
In related news, VP Rita A. Karachun sold 5,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, August 2nd. The shares were sold at an average price of $65.01, for a total transaction of $325,050.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Kenneth C. Frazier sold 279,850 shares of Merck & Co., Inc. stock in a transaction dated Tuesday, October 2nd. The shares were sold at an average price of $72.07, for a total transaction of $20,168,789.50. Following the transaction, the chairman now directly owns 971,800 shares of the company’s stock, valued at $70,037,626. The disclosure for this sale can be found here. Over the last three months, insiders have sold 701,269 shares of company stock valued at $49,544,684. 0.32% of the stock is currently owned by corporate insiders.
NYSE:MRK opened at $71.45 on Tuesday. Merck & Co., Inc. has a 12 month low of $52.83 and a 12 month high of $73.49. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.33 and a quick ratio of 1.04. The stock has a market capitalization of $189.81 billion, a PE ratio of 17.95, a P/E/G ratio of 2.15 and a beta of 0.81.
Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, October 25th. The company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. Merck & Co., Inc. had a net margin of 8.44% and a return on equity of 34.20%. The company had revenue of $10.79 billion during the quarter, compared to analysts’ expectations of $10.87 billion. As a group, research analysts forecast that Merck & Co., Inc. will post 4.33 earnings per share for the current year.
Merck & Co., Inc. declared that its Board of Directors has initiated a share repurchase plan on Thursday, October 25th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the company to repurchase up to 5.1% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, January 8th. Investors of record on Monday, December 17th will be given a dividend of $0.55 per share. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.48. This represents a $2.20 dividend on an annualized basis and a yield of 3.08%. The ex-dividend date is Friday, December 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 48.24%.
Merck & Co., Inc. Company Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.